Last reviewed · How we verify
Darbepoetin alfa SC
At a glance
| Generic name | Darbepoetin alfa SC |
|---|---|
| Sponsor | Amgen |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants (PHASE3)
- Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND) (PHASE3)
- Trial to Reduce Cardiovascular Events With Aranesp® Therapy (TREAT) (PHASE3)
- Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease (PHASE3)
- Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D) (PHASE3)
- Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis (PHASE3)
- Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID) (PHASE3)
- A Study of Once Monthly Intravenous or Subcutaneous Mircera in Participants With Chronic Kidney Disease on Hemodialysis. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Darbepoetin alfa SC CI brief — competitive landscape report
- Darbepoetin alfa SC updates RSS · CI watch RSS
- Amgen portfolio CI